Skip to main content
Clinical Trials/NCT06030596
NCT06030596RecruitingNot Applicable

SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve

China National Center for Cardiovascular Diseases1 site in 1 country210 target enrollmentStarted: September 9, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
210
Locations
1
Primary Endpoint
The diagnostic accuracy of MBF and MFR derived from SPECT

Study Overview

Brief Summary

Recent evidences have demonstrated improved diagnostic accuracy for detecting coronary artery disease (CAD) when myocardial blood flow (MBF) is quantified in absolute terms using single photon emission tomography (SPECT) compared to conventional myocardial perfusion imaging (MPI). However, there are no uniformly accepted cutoff values of MBF and MFR derived from SPECT for diagnosing hemodynamically significant CAD. Particularly, the diagnostic performance for quantitative SPECT has not been validated using fractional flow reserve (FFR). The aim of this prospective study is to determine optimal cutoff values of absolute MBF and MFR derived from NaI (Tl)-based SPECT and to evaluate the diagnostic efficacy of this quantitative technology utilizing invasive coronary angiography (ICA) in combination with FFR results as the reference standard in patients with suspected or known CAD.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 79 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18 ~ 79 years old
  • At least one CAD risk factor
  • Intermediate to high pre-test likelihood for CAD
  • Suspected or known CAD, clinically referred for invasive coronary angiography
  • Able and willing to comply with the study procedures
  • Written informed consent

Exclusion Criteria

  • History or risk of severe bradycardia
  • History of myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy, valve issue or congenital heart disease
  • Wheezing asthma or COPD
  • Known second- or third-degree AV block
  • Known hypersensitivity to dipyridamole or adenosine
  • Known coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) prior to screening
  • Breastfeeding or pregnancy
  • Claustrophobia or inability to lie still in a supine position
  • Unwillingness or inability to provide informed consent

Outcomes

Primary Outcomes

The diagnostic accuracy of MBF and MFR derived from SPECT

Time Frame: 1 year

The diagnostic sensitivity, specificity, accuracy of MBF and MFR derived from SPECT for the detection of hemodynamically significant coronary artery disease as defined by invasive coronary angiography in combination with fractional flow reserve measurements.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
China National Center for Cardiovascular Diseases
Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Wei Fang

MD

China National Center for Cardiovascular Diseases

Study Sites (1)

Loading locations...

Similar Trials